Lysosomal Therapeutics Inc. (LTI) is dedicated to innovative, research and development in the field of neurodegeneration. Their strategy leverages the genetically and clinically validated link between lysosomal disorders and neurodegenerative diseases to establish a unique and effective platform for novel drug discovery.
